Optimized Hamster Reg3 Gamma Peptide for Beta Cell Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetes, particularly type 1 and type 2, fail to sustainably generate new beta cells, leading to ongoing insulin dependence due to autoimmune destruction and limited beta cell regeneration, with existing therapies causing tolerability issues and insufficient long-term insulin independence.
Innovation Solution
An optimized 15-amino acid hamster Reg3 gamma peptide, combined with an immune tolerance agent like Cyclosporine, is used to transform pancreatic ductal cells into new islets, promoting beta cell regeneration and protecting newly formed cells from autoimmune destruction, thereby achieving insulin independence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing diabetes therapies are used, then insulin dependence is maintained, but beta cell regeneration is insufficient and autoimmune destruction continues
Solution Approach 1:
The patent applies preliminary action by administering the optimized hamster Reg3 gamma peptide before significant beta cell loss occurs, aiming to stimulate ductal cell transformation into beta cells in advance. This preventive approach seeks to establish a reservoir of new beta cells before autoimmune destruction becomes irreversible, thereby improving reliability of beta cell regeneration while maintaining insulin production capability.
Solution Approach 2:
The patent employs parameter changes by optimizing the hamster Reg3 gamma peptide sequence to enhance its stability and biological activity. Specific amino acid modifications were made to improve the peptide's half-life and efficacy in stimulating beta cell formation, directly addressing the insufficient beta cell regeneration while preserving insulin production function.
2Reliability
If hamster Reg3 gamma peptide is administered, then beta cell generation is enhanced, but tolerability issues and instability occur
Solution Approach 1:
The patent directly addresses peptide stability by modifying the amino acid sequence of hamster Reg3 gamma peptide. Specific parameter changes include optimizing disulfide bond positioning, adjusting hydrophobicity, and enhancing resistance to proteolytic degradation. These modifications improve the peptide's compositional stability while maintaining its ability to generate beta cells.
Solution Approach 2:
The patent creates a composite therapeutic approach by combining the optimized hamster Reg3 gamma peptide with immune tolerance agents. This composite strategy not only enhances beta cell generation but also improves overall treatment stability by protecting newly formed beta cells from autoimmune destruction, thereby addressing both reliability and stability parameters simultaneously.
3Reliability
If immune tolerance agents are combined with optimized peptide, then insulin independence is achieved, but treatment complexity increases
Solution Approach 1:
The patent merges multiple therapeutic functions into a unified treatment regimen by combining the optimized hamster Reg3 gamma peptide with immune tolerance agents. This combination therapy addresses both beta cell regeneration and autoimmune protection simultaneously, achieving insulin independence while managing treatment complexity through coordinated administration protocols.
Solution Approach 2:
The optimized hamster Reg3 gamma peptide serves multiple functions: it stimulates ductal cell transformation into beta cells, enhances insulin production, and when combined with immune tolerance agents, provides comprehensive protection against autoimmune destruction. This multi-functionality reduces the need for separate targeted therapies, thereby managing treatment complexity while achieving insulin independence.
Data Source
AI summary
Embodiments of the present invention provide for novel therapies, pharmaceutical compositions and methods for insulin independence utilizing a new optimized hamster Reg3 gamma peptide, which is new to the art and has not previously been considered for development in the 30 year history since its discovery. Methods, pharmaceutical compositions and therapies novel to the prior art are utilized in this invention to render patients with recent onset and existing type 1 diabetes insulin independent by an optimized hamster Reg3 gamma peptide and an immune tolerance agent for type 1 patients to become insulin independent and used alone without an immune tolerance agent for type 2 diabetes. While not wishing to be bound by theory, optimized Reg3 gamma peptides increases beta cell generation by its demonstrated properties shown within of transforming ductal pancreatic cells into new islets.